Abelacimab Versus Rivaroxaban in Patients With Atrial Fibrillation Receiving Oral Antiplatelet Therapy: Definitely Safe, but How Effective?
P
Philippe Gabriel Steg
(French Alliance for Cardiovascular Trials, Paris)
J
Jules Mesnier
(Université Paris-Cité, Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, French Alliance for Cardiovascular Trials, INSERM-U1148, Paris, France.)
Article Details
Journal
Circulation
Volume / Issue
Vol. 152, Issue 5
Published
August 05, 2025
Pages
297-299
ISSN
0009-7322
Publisher
Lippincott Williams & Wilkins
Authors (2)
P
Philippe Gabriel Steg
French Alliance for Cardiovascular Trials, Paris
J
Jules Mesnier
Université Paris-Cité, Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, French Alliance for Cardiovascular Trials, INSERM-U1148, Paris, France.
Related Articles from this Journal
Occupational Radiation Safety in Electrophysiology During Pregnancy: Evaluating Uterine Radiation Doses During Catheter Ablations and Device Implantations
Johanna Mueller-Leisse, Henrike Aenne Katrin Hillmann et al.
Aug 2026
10.1161/circulationaha.126.080556
Response by Rogers et al to Letter Regarding, “Deep Learning-Based Continuous QT Monitoring to Identify High-Risk Prolongation Events After Class III Antiarrhythmic Initiation”
Albert J. Rogers, Sabyasachi Bandyopadhyay et al.
Aug 2026
10.1161/circulationaha.126.080755
Clinical Cardiology at the Crossroads: Perspectives on the Next Era at <i>Circulation</i>
Jennifer E. Ho, Ryan J. Tedford
Aug 2026
10.1161/circulationaha.126.080205
ABHD11-Mediated mtDNA Transcription Restored Mitochondrial Function to Attenuate Cardiomyocyte Ferroptosis After Myocardial Infarction
Yu Liu, Yijin Chen et al.
Aug 2026
10.1161/circulationaha.125.078593
Letter by Li et al Regarding Article, “Deep Learning-Based Continuous QT Monitoring to Identify High-Risk Prolongation Events After Class III Antiarrhythmic Initiation”
Dong Li, Shuang Zhang et al.
Aug 2026
10.1161/circulationaha.126.079996